TerraPower and Cardinal Health (NYSE: CAH) announced an agreement that will help advance the next generation of cancer treatment. Under the agreement, the companies will work together to develop and produce Actinium-225 for use in drug development and commercial sales.
Under
this agreement, Cardinal Health will produce and distribute TerraPower’s
Actinium-225 product, which will be utilized in drug trials involving targeted
alpha therapy for diseases such as breast, prostate, colon and neuroendocrine
cancers, melanoma and lymphoma. The current global supply of Actinium-225 is very
limited, but with this agreement, it is anticipated that the companies will be
able to significantly increase availability of the radionuclide.
To
read more please visit:
Source: WebWire